Medical Foods For Orphan Diseases Market To Reach $2.2 Billion By 2033

Medical Foods For Orphan Diseases Market Growth & Trends

The global medical foods for orphan diseases market size is expected to reach USD 2.2 billion by 2033. It is expected to expand at a CAGR of 5.4% from 2026 to 2033, according to a new report by Grand View Research, Inc. The major factors contributing to the industry’s growth are the growing prevalence of orphan diseases and increasing awareness about such rare conditions. Moreover, rising government initiatives for early screening and increasing initiatives by key players to develop products that cater to such niche segments also spell a promising horizon of growth.

Special medical nutritional requirements are needed for a variety of rare diseases in order to prevent major disabilities and allow normal growth in children and adults. Conditions like food protein-induced maple syrup urine disease, short bowel syndrome, and others, require special dietary requirements in order to maintain robust health. The growing awareness of such rare conditions and increased efficacy of diet plans also promise more avenues for growth.

Medical foods are expensive and may or may not be covered under health insurance. Since the FDA does not classify medicinal foods as drugs, many insurance plans do not cover them. This can impede market expansion over the forecast period.

Unlike other industries, COVID-19 had a positive impact on market growth. The increased awareness about immunity and healthy foods led to a significant rise in the adoption rate of clinical foods. In the year 2020, consumers opted for much healthier diets encompassing nutritional support and dietetic care as compared to the year 2019.

The oral segment dominated the market with a revenue share of over 69.5% in 2022. The oral route for medicinal foods remains the most convenient, and hassle-free. Hence, it remains the most preferred route for consumers globally and oral products are easily available. The expanding production of oral goods in the form of tablets, powder, and pre-thickened products also remains a prominent driver of growth.

The powder segment accounted for the largest revenue share of over 35.4% in 2022. Easy commercial availability of medicinal foods in powdered form is largely responsible for the segment's expansion. Additionally, powered forms of products are simple to use and hence widely preferred by pediatric and geriatric patients suffering from various rare diseases, which continues to drive the segment's expansion.

The institutional sales channel accounted for the largest revenue share of over 41.2% in 2022. The segment includes home care settings, hospitals, and disability facilities. The online sales segment is anticipated to expand at the fastest rate over the forecast period. Due to the convenience, these sales channel provides, more people choose to buy medicinal foods online.

 Request a free sample copy or view report summary: Medical Foods For Orphan Diseases Market Report

Medical Foods For Orphan Diseases Market Report Highlights

• The powder segment dominated the medical foods for orphan diseases market with a revenue share of 35.7% in 2025. The dominance is attributed to the widespread availability of disease-specific powdered medical foods for inherited metabolic disorders such as phenylketonuria, maple syrup urine disease, and tyrosinemia.

• The oral segment dominated the medical foods for orphan diseases industry with a revenue share of 69.0% in 2025. Oral administration remains the preferred route for managing inherited metabolic disorders such as phenylketonuria, maple syrup urine disease, and tyrosinemia, owing to its ease of long-term use and high patient compliance.

• The eosinophilic esophagitis segment accounted for a significant share of 14.0% the medical foods for orphan diseases market in 2025, driven by rising disease prevalence and greater adoption of elimination diets and amino acid-based medical foods for long-term nutritional management.

• The institutional sales segment dominated the medical foods for orphan diseases industry with a revenue share of 40.1% in 2025. This is driven by the high volume of medical foods dispensed through hospitals, metabolic clinics, specialty care centers, and long-term care facilities.

• In 2025, North America held the largest revenue share of over 34.2%. Asia Pacific is anticipated to be the fastest-growing regional market over the forecast period. Increasing penetration rate, awareness, growing use of medical foods, and several key government initiatives remain the cornerstone of its growth

Medical Foods For Orphan Diseases Market Segmentation

Grand View Research has segmented the global medical foods for orphan diseases market based on route of administration, product, sales channel, application, and region:

Medical Foods For Orphan Diseases Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)

• Oral

• Enteral

Medical Foods For Orphan Diseases Product Outlook (Revenue, USD Million, 2021 - 2033)

• Powder

• Pills

• Liquid

• Others

Medical Foods For Orphan Diseases Application Outlook (Revenue, USD Million, 2021 - 2033)

• Tyrosinemia

• Eosinophilic Esophagitis

• FPIES

• Phenylketonuria

• MSUD

• Homocystinuria

• Others

Medical Foods For Orphan Diseases Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)

• Online Sales

• Retail Sales

• Institutional Sales

Medical Foods For Orphan Diseases Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • Spain

  • France

  • Italy

  • Denmark

  • Sweden

  • Norway

  • Russia

• Asia Pacific

  • Japan

  • China

  • Australia

  • India

  • South Korea

  • Thailand

  • Singapore

  • New Zealand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • South Africa

  • Kuwait

List of Key Players of Medical Foods For Orphan Diseases Market

• Danone

• Nestlé

• Cambrooke Therapeutics, Inc.

• Ajinomoto Cambrooke, Inc.

• Reckitt Benckiser Group plc (Mead Johnson Nutrition)

• Dr. Schär AG

• metaX Institut für Diätetik GmbH

• Promin Metabolic Nutrition

• Aminolab Sp. z o.o.

• Galen Limited

• Applied Nutrition Corp.

• PKU Perspectives, Inc.